Tirzepatide dual incretin therapy for obesity
New England Journal of Medicine
2022
Study summary
Tirzepatide evaluated as dual GIP/GLP-1 receptor agonist.
Peptides studied
Goals studied
Stack studied
Advanced Metabolic Stack
Key findings
Significant body weight reductions observed in clinical trials.
Study details
Study type
randomized clinical trial
Journal
New England Journal of Medicine
DOI / PubMed
10.1056/NEJMoa2206038
Year
2022
Explore peptide profiles
Discover compounds, understand their mechanisms, and explore the research behind each peptide.
